Physician profile
Ghayth M Hammad
NPI 1184719874
$2,773.61
in general payments reported to CMS, 2019-2025
42 companies · $562 in 2025
The $562 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $246 · 2021: $471 · 2022: $335 · 2023: $302 · 2024: $384 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $390.58 | 2019-2025 | |
| Amgen INC. | $377.20 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $266.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $216.09 | 2021-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $175.95 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.77 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $118.87 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $102.51 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $83.99 | 2019-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $77.27 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $60.41 | 2021-2025 | Breztri, Farxiga |
| Astellas Pharma US INC | $53.73 | 2020-2024 | Veozah, Myrbetriq |
| Halozyme INC | $50.00 | 2023 | |
| Allergan, INC. | $43.55 | 2019-2020 | |
| Exact Sciences Corporation | $42.24 | 2024-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghayth Hammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.